Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
206.27
-0.88 (-0.42%)
At close: Aug 27, 2026, 4:00 PM EDT
206.00
-0.27 (-0.13%)
After-hours: Aug 27, 2026, 4:55 PM EDT
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $218.38M in the quarter ending June 30, 2026, with 45.54% growth. This brings the company's revenue in the last twelve months to $776.57M, up 56.87% year-over-year. In the year 2025, Axsome Therapeutics had annual revenue of $638.50M with 65.55% growth.
Revenue (ttm)
$776.57M
Revenue Growth
+56.87%
P/S Ratio
13.89
Revenue / Employee
$576,946
Employees
1,346
Market Cap
10.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 638.50M | 252.80M | 65.55% |
| Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
| Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
| Dec 31, 2022 | 50.04M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.66B |
| Bio-Techne | 1.22B |
| Ionis Pharmaceuticals | 874.09M |
| Krystal Biotech | 440.48M |
| Protagonist Therapeutics | 281.99M |
| Kymera Therapeutics | 105.00M |
| Cytokinetics | 67.67M |
| Praxis Precision Medicines | 7.46M |
AXSM News
- 10 days ago - Axsome Therapeutics price target raised to $316 from $306 at Mizuho - TheFly
- 16 days ago - Axsome Therapeutics price target lowered to $297 from $304 at RBC Capital - TheFly
- 16 days ago - Axsome Therapeutics price target raised to $251 from $242 at Morgan Stanley - TheFly
- 16 days ago - Axsome Therapeutics price target raised to $275 from $260 at Guggenheim - TheFly
- 16 days ago - Axsome Therapeutics price target raised to $256 from $255 at Wells Fargo - TheFly
- 17 days ago - Axsome Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 17 days ago - Axsome Therapeutics Earnings release: Q2 2026 - Filings
- 17 days ago - Axsome Therapeutics Slides: Q2 2026 - Filings